Phase 1 Study on Food Impact on Cytisinicline Bioavailability and Pharmacokinetics in Healthy Adult Smokers

The primary objective of this study is to evaluate the effect of food on the **bioavailability** of a single 3 mg tablet of **Cytisinicline** in healthy adult smokers. This is clinically relevant as understanding the impact of food on drug absorption can inform dosing recommendations and optimize therapeutic efficacy. Additionally, the study aims to assess the **pharmacokinetics** of multiple 3 mg doses administered three times daily. This information is crucial for determining the appropriate dosing regimen and ensuring consistent drug exposure in patients. The study does not focus on any specific medical condition, as it involves healthy adult smokers.

The clinical trial involves a **study population** comprising both male and female participants, with an age range that includes adolescents and adults. The trial does not focus on individuals with any specific **medical condition**, as indicated by the absence of a targeted condition. The sponsor has not provided information regarding the total number of participants involved in the study. The trial population selection includes a vulnerable population, although specific details about lifestyle considerations such as diet, physical activity, or habits have not been disclosed. The sponsor has not provided key inclusion or exclusion criteria for this trial.

The clinical trial is designed as a **Phase 1** study to evaluate the effect of food on the bioavailability of a single 3 mg cytisinicline tablet and to assess the pharmacokinetics of multiple 3 mg doses administered three times daily in healthy adult smokers. The trial follows a randomized, double-blind, controlled design to ensure the reliability and validity of the results. The estimated duration of the trial spans from August 2, 2023, to September 8, 2023, encompassing both the recruitment and study phases.

Participants will undergo a sequence of study visits, beginning with an inclusion (screening) visit to determine eligibility based on predefined criteria. This initial visit will involve assessments to confirm the absence of any medical conditions that could interfere with the study outcomes. Following successful screening, participants will be enrolled in the trial and will attend multiple follow-up visits. These visits are structured to monitor the pharmacokinetic parameters and to ensure participant safety throughout the study duration. The end-of-study visit will conclude the trial, during which final assessments will be conducted to gather comprehensive data on the study endpoints.

The expected length of participant involvement is approximately five weeks, covering the entire trial period from screening to the end-of-study visit. Conditions that may lead to early termination from the study include non-compliance with study protocols, adverse events that compromise participant safety, or withdrawal of consent by the participant. The trial is conducted under strict adherence to ethical guidelines and regulatory requirements to ensure the integrity of the data and the safety of the participants.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the lack of specific data, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be detailed. The absence of this information precludes the provision of a comprehensive description of the treatments used in this clinical trial.

The clinical trial is in Phase 3, with an estimated recruitment start date of August 2, 2023, and an estimated end date of September 8, 2023. Efficacy will be assessed through a structured evaluation process, although specific parameters or endpoints for efficacy assessment are not provided. The trial will follow a systematic approach to measure, collect, and analyze data, adhering to the standards expected in Phase 3 trials. The trial's design will ensure that efficacy assessments are conducted at predetermined intervals, utilizing appropriate tools and instruments to ensure the reliability and validity of the data collected. The analysis will be performed in accordance with the trial's protocol, ensuring that the results are scientifically robust and clinically meaningful.